PharmaSwiss Česká republika s.r.o., Praha - search results

European Union - English - EMA (European Medicines Agency)

mysimba

orexigen therapeutics ireland limited - bupropion hydrochloride, naltrexone hydrochloride - obesity; overweight - antiobesity preparations, excl. diet products - mysimba is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial body mass index (bmi) of≥ 30 kg/m2 (obese), or≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)treatment with mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.

European Union - English - EMA (European Medicines Agency)

urorec

recordati ireland ltd - silodosin - prostatic hyperplasia - urologicals - treatment of the signs and symptoms of benign prostatic hyperplasia (bph).

European Union - English - EMA (European Medicines Agency)

voncento

csl behring gmbh - human coagulation factor viii, human von willebrand factor - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - von willebrand disease (vwd)prophylaxis and treatment of haemorrhage or surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated.haemophilia a (congenital factor-viii deficiency)prophylaxis and treatment of bleeding in patients with haemophilia a.